摘要
目的:二肽基肽酶-4(DPP-4)抑制剂的问世是21世纪药学研究的丰硕成果,其作用途径独特,迂回在胰岛β细胞和胰岛素之外,通过抑制DPP-4活性延长胰高血糖素样肽-1(GLP-1)的作用时间和促进胰岛素分泌,从而降低血糖水平,本文对其作用特点和临床应用进行评价。方法:通过对国内外近期文献进行分析。结果与结论:DPP-4抑制剂通过抑制内源性的GLP-1的降解,提高GLP-1的水平,进而促进葡萄糖依赖的胰岛素分泌和抑制胰高血糖素产生,从而控制血糖的稳定。DPP-IV抑制剂具有不影响体质量和不增加低血糖风险的优势,在2型糖尿病的治疗中发挥着越来越重要的作用。
Dipeptidyl peptidase-4 (DPP-4) Inhibitor has pharmaceutical research fruitful results of twenty-first century, it has unique effect channel, except circuitous pancreatic islet-beta cells and insulin, the inhibition of DPP-4 can prolong the action of glucagon-like peptide-land improve insulin secretion, so as to lower the glucose level, to summarize the aspect of clinical application and evaluation. METHODS:To collecte medical literatures in recent years at home and abroad. RESULTS & CONCLUSION:the dipeptidyl pepdase-4inhibitor is a validated target for the treatment of type 2 diabetes. DPP-4 inhibitor significantly lower bloodglueose levels in patients with type 2 diabetes without common side effects of body weight gain, hypoglycemia and gastrointestinal disturbances, therfore, DPP-4 inhibitor play an increasingly important role in the treatment of type 2 diabetes.
出处
《中国医院用药评价与分析》
2013年第4期301-305,共5页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
途径
二肽基肽酶-4抑制剂
进展
安全性评价
Gateway
Dipeptidyl peptidase- IV (DPP-4) inhibitor
Progress
Safety evaluation